Organogenesis Holdings Inc. (ORGO)
| Market Cap | 308.74M |
| Revenue (ttm) | 564.17M |
| Net Income (ttm) | 20.02M |
| Shares Out | 128.64M |
| EPS (ttm) | 0.15 |
| PE Ratio | 16.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 992,914 |
| Open | 2.380 |
| Previous Close | 2.390 |
| Day's Range | 2.360 - 2.445 |
| 52-Week Range | 2.210 - 7.077 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+254.17%) |
| Earnings Date | May 7, 2026 |
About ORGO
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ORGO stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 254.17% from the latest price.
News
What's Going On With Organogenesis Stock On Wednesday?
Organogenesis Holdings Inc. (NASDAQ:ORGO) shares are up during Wednesday's premarket session following positive news regarding a clinical trial for PuraPly AM, which demonstrated statistically signifi...
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win
The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM plus standard of care to standard care alone.
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of p...
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the d...
Organogenesis Holdings Earnings Call Transcript: Q4 2025
Record Q4 and 2025 revenue driven by advanced wound care, but 2026 faces a 25%-38% revenue decline due to CMS policy changes and clinician confusion. Management expects recovery and market share gains in the second half of 2026, supported by new investments and product innovation.
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the de...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
CANTON, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of pr...
Organogenesis Announces Initiation of Biologics License Application for ReNu®
Initial modules submitted to FDA under rolling review; final modules expected in the first half of 2026 Initial modules submitted to FDA under rolling review; final modules expected in the first half ...
Organogenesis Holdings Earnings Call Transcript: Q3 2025
Q3 2025 revenue and earnings exceeded expectations, led by 31% growth in advanced wound care and 25% in surgical and sports medicine. CMS payment reforms and strong product positioning set the stage for continued growth, with 2025 guidance raised across key metrics.
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Organogenesis Applauds CMS's Significant Step In Payment Reform
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond With evidence-based portfolio including ...
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commer...
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
LOS ANGELES--(BUSINESS WIRE)--Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO.
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Why Is Organogenesis Stock Trading Lower Friday?
Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for th...
Organogenesis Provides Update on Second Phase 3 ReNu® Study
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not m...
Organogenesis Holdings Transcript: Cantor Global Healthcare Conference 2025
A major regulatory shift will standardize reimbursement and focus competition on clinical efficacy. New product launches and manufacturing expansion are driving growth, with a strong pipeline including ReNu targeting the pain management market. Financials remain solid with a positive outlook.
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Organogenesis Holdings Earnings Call Transcript: Q2 2025
Q2 revenue declined 23% year-over-year, with advanced wound care impacted by regulatory delays and aggressive pricing, while surgical and sports medicine grew 16%. 2025 guidance was tightened, with new CMS payment reforms expected to benefit the business in 2026.
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation
CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p...
Organogenesis Holdings Earnings Call Transcript: Q1 2025
Q1 2025 revenue declined 21% year-over-year but met guidance amid LCD policy uncertainty. The company reaffirmed 2025 guidance, expects business improvement in the second half, and is advancing clinical programs and manufacturing expansion.
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr...